Los Angeles Capital Management LLC Has $1.80 Million Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

Los Angeles Capital Management LLC trimmed its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) by 1.0% in the third quarter, Holdings Channel reports. The institutional investor owned 9,884 shares of the company’s stock after selling 100 shares during the period. Los Angeles Capital Management LLC’s holdings in Krystal Biotech were worth $1,799,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Scout Investments Inc. bought a new position in Krystal Biotech during the 1st quarter worth $8,976,000. Sei Investments Co. increased its position in shares of Krystal Biotech by 128.3% in the first quarter. Sei Investments Co. now owns 33,752 shares of the company’s stock worth $6,005,000 after purchasing an additional 18,968 shares during the period. Price T Rowe Associates Inc. MD raised its stake in Krystal Biotech by 54.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 658,618 shares of the company’s stock valued at $117,189,000 after purchasing an additional 231,255 shares in the last quarter. Shaker Investments LLC OH bought a new stake in Krystal Biotech during the third quarter worth about $532,000. Finally, Amalgamated Bank lifted its position in Krystal Biotech by 937.9% during the second quarter. Amalgamated Bank now owns 7,577 shares of the company’s stock worth $1,391,000 after purchasing an additional 6,847 shares during the period. 86.29% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently commented on KRYS shares. Cantor Fitzgerald restated an “overweight” rating on shares of Krystal Biotech in a research report on Thursday, August 29th. HC Wainwright reissued a “buy” rating and issued a $221.00 price objective on shares of Krystal Biotech in a research note on Tuesday, November 5th. Citigroup upped their target price on Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Evercore ISI boosted their price target on Krystal Biotech from $201.00 to $206.00 and gave the stock an “outperform” rating in a report on Monday, August 12th. Finally, Chardan Capital raised their price objective on Krystal Biotech from $153.00 to $208.00 and gave the company a “buy” rating in a research note on Monday, August 5th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $197.00.

Insider Activity

In related news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $197.76, for a total value of $4,944,000.00. Following the sale, the insider now owns 1,500,882 shares of the company’s stock, valued at $296,814,424.32. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 14.10% of the company’s stock.

Krystal Biotech Stock Down 1.6 %

Shares of KRYS opened at $184.22 on Thursday. The stock has a market cap of $5.30 billion, a PE ratio of 104.08 and a beta of 0.82. Krystal Biotech, Inc. has a 12-month low of $96.73 and a 12-month high of $219.34. The business has a 50-day simple moving average of $181.31 and a two-hundred day simple moving average of $181.36.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings data on Monday, November 4th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.84 by $0.07. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The company had revenue of $83.84 million during the quarter, compared to the consensus estimate of $82.94 million. During the same quarter in the prior year, the firm posted ($0.67) earnings per share. The firm’s revenue was up 879.9% compared to the same quarter last year. On average, equities research analysts expect that Krystal Biotech, Inc. will post 2.97 EPS for the current year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).